These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 29155816)
21. Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B. Paradisi A; Capizzi R; Zampetti A; Proietti I; De Simone C; Feliciani C; Amerio PL J Infect; 2005 Dec; 51(5):e261-4. PubMed ID: 15936088 [TBL] [Abstract][Full Text] [Related]
22. Treatment of imported New World cutaneous leishmaniasis in Germany. Harms G; Scherbaum H; Reiter-Owona I; Stich A; Richter J Int J Dermatol; 2011 Nov; 50(11):1336-1342. PubMed ID: 22004484 [TBL] [Abstract][Full Text] [Related]
23. Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review. Mosimann V; Neumayr A; Paris DH; Blum J Acta Trop; 2018 Jun; 182():246-250. PubMed ID: 29550282 [TBL] [Abstract][Full Text] [Related]
24. American Cutaneous Leishmaniasis: Imported cases in Berlin 2000-2023. Lindner AK; Moreno-Del Castillo MC; Wintel M; Equihua Martinez G; Richter J; Kurth F; Pfäfflin F; Zoller T; Gertler M; Georgi S; Nürnberg M; Hülso C; Bernhard J; Kotsias SK; Seigerschmidt A; van Loon W; Mockenhaupt F; Kampmann B; Harms G PLoS Negl Trop Dis; 2024 Jul; 18(7):e0012323. PubMed ID: 39008517 [TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of liposomal amphotericin B in hospitalised patients with mucocutaneous leishmaniasis. Mistro S; Gomes B; Rosa L; Miranda L; Camargo M; Badaró R Trop Med Int Health; 2017 Dec; 22(12):1569-1578. PubMed ID: 29078022 [TBL] [Abstract][Full Text] [Related]
27. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. Solomon M; Baum S; Barzilai A; Scope A; Trau H; Schwartz E J Am Acad Dermatol; 2007 Apr; 56(4):612-6. PubMed ID: 17276541 [TBL] [Abstract][Full Text] [Related]
28. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Wortmann G; Zapor M; Ressner R; Fraser S; Hartzell J; Pierson J; Weintrob A; Magill A Am J Trop Med Hyg; 2010 Nov; 83(5):1028-33. PubMed ID: 21036832 [TBL] [Abstract][Full Text] [Related]
29. Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis: a preliminary report. Mushtaq S; Dogra D; Dogra N Dermatol Ther; 2016 Nov; 29(6):398-405. PubMed ID: 27477764 [TBL] [Abstract][Full Text] [Related]
30. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Brown M; Noursadeghi M; Boyle J; Davidson RN Br J Dermatol; 2005 Jul; 153(1):203-5. PubMed ID: 16029352 [TBL] [Abstract][Full Text] [Related]
31. Treatment of pediatric cutaneous leishmaniasis with liposomal amphotericin B. Erat T; An I Dermatol Ther; 2022 Sep; 35(9):e15706. PubMed ID: 35810338 [TBL] [Abstract][Full Text] [Related]
32. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience. Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166 [TBL] [Abstract][Full Text] [Related]
33. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis. Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275 [TBL] [Abstract][Full Text] [Related]
34. Successful treatment of childhood cutaneous leishmaniasis with liposomal amphotericin B: report of two cases. del Rosal T; Artigao FB; Miguel MJ; de Lucas R; del Castillo F J Trop Pediatr; 2010 Apr; 56(2):122-4. PubMed ID: 19656844 [TBL] [Abstract][Full Text] [Related]
35. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles. Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828 [TBL] [Abstract][Full Text] [Related]
36. Cutaneous leishmaniasis caused by Leishmania infantum in Southern Israel. Ben-Shimol S; Sagi O; Horev A; Avni YS; Ziv M; Riesenberg K Acta Parasitol; 2016 Dec; 61(4):855-858. PubMed ID: 27787222 [TBL] [Abstract][Full Text] [Related]
37. Amphotericin B Deoxycholate Treatment of Post-Kala-Azar Dermal Leishmaniasis in India. Sundar S; Chakravarty J; Singh J; Verma D; Agrawal N; Dinkar A Am J Trop Med Hyg; 2024 Jul; 111(1):59-63. PubMed ID: 38834057 [TBL] [Abstract][Full Text] [Related]
38. Current and emerging medications for the treatment of leishmaniasis. Chakravarty J; Sundar S Expert Opin Pharmacother; 2019 Jul; 20(10):1251-1265. PubMed ID: 31063412 [TBL] [Abstract][Full Text] [Related]
39. To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL). Rabi Das VN; Siddiqui NA; Pal B; Lal CS; Verma N; Kumar A; Verma RB; Kumar D; Das P; Pandey K PLoS One; 2017; 12(3):e0174497. PubMed ID: 28355259 [TBL] [Abstract][Full Text] [Related]
40. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. Motta JO; Sampaio RN J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):331-5. PubMed ID: 21492255 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]